1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020. doi: 10.1056/NEJMoa2034577 .

2. Gov.UK. Confirmation of guidance to vaccination centres on managing allergic reactions following COVID-19 vaccination with the Pfizer/BioNTech vaccine. Press release [Internet]. Disponível em:https://www.gov.uk/government/news/confirmation-of-guidanceto-vaccination-centres-on-managing-allergic-reactions-followingcovid-19-vaccination-with-the-pfizer-biontech-vaccine. Acessado em: 20/12/2020.

3. CDC - Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of mRNA COVID19 Vaccines Currently Authorized in the United States [Internet]. Disponível em: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html. Acessado em: 20/12/2020.

4. Giavina-Bianchi P, Aun MV, Kalil J. Drug-induced anaphylaxis: is it an epidemic? Curr Opin Allergy Clin Immunol. 2018;18(1):59-65.

5. Giavina-Bianchi P, Kalil J. Polyethylene Glycol Is a Cause of IgE-Mediated Anaphylaxis. J Allergy Clin Immunol Pract. 2019;7(6):1874-5.

6. Fernandes FR, Marinho AKBB, da Silva MAA, Anagusko CLY, Antunes AA, Valente CFC, et al. Vacinas COVID-19 e reações imunoalérgicas. Arq Asma Alerg Imunol. 2020;4(3):273-6.